Neurosense Therapeutics is trading 15.4% higher at $4.54; its October 2 plan to appeal Nasdaq’s minimum market-value determination is the clearest relevant company news, though reporting does not confirm it drove the October 5 move. - The company failed to meet the $35 million requirement and plans to seek more time to regain compliance; a timely hearing request would stay suspension while the panel considers the case. - Shares had declined for several sessions; broader indices were mixed, so no market-wide explanation is evident.